Role of FDG-PET/CT in diagnosis, staging, response to treatment, and prognosis of pancreatic cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 2, 2011, Pages 111-114

  Grassetto, Gaia ^a   Rubello, Domenico ^a  

^a 'Santa Maria della Misericordia' Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; ACETIC ACID C 11; ANTINEOPLASTIC AGENT;

CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; ECHOGRAPHY; HISTOLOGY; HUMAN; LAPAROTOMY; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MALIGNANT TRANSFORMATION; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT OUTCOME;

FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS;

EID: 79955971299     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181d275a0     Document Type: Review

References (34)

1. Evans DD, Wolf RA, Crane CH, et al. Carcinoma del pancreas. In: Pollock RE, Doroshok JH, Khayat D, et al. UICC Manuale di Oncologia Clinica. Italian edition by Badellino F, Beretta G. Minerva Medica Publisher, Torino, Italy; 2008:487-510.
2. 11C-acetate: a comparison study with 18 F-FDG. Nucl Med Commun. 2009;30:971-977.
3. Wakabayashi H, Nishiyama Y, Otani T, et al. Role of 18 F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer. World J Gastroenterol. 2008;14:64-69. (Pubitemid 351314328)
4. Heihrich S, Goerres GW, Schafer M, et al. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg. 2005;242:235-243. (Pubitemid 41033440)
5. Miura F, Takada T, Amano H, et al. Diagnosis of pancreatic cancer. HPB. 2006;8:337-342. (Pubitemid 44473457)
6. Bang S, Chung HW, Park SW, et al. The clinical usefulness of 18-Fluoro-deoxyglucose positron emission tomography in the differential diagnosis, staging and response evaluation after concurrent chemioradiotherapy for pancreatic cancer. J Clin Gastroenterol. 2006;40:923-929. (Pubitemid 44690768)
7. Parson CM, Sutcliffe JL, Bold RJ. Preoperative evaluation of pancreatic adenocarcinoma. J Hepatobiliary Pancreat Surg. 2008;15:429-435.
8. Li D, Xie K, Wolff R, et al. Pancreatica cancer. Lancet. 2004;363:1049-1057.
9. Pakzad F, Groves AM, Ell PJ. The role of positron emission tomography in the management on pancreatica cancer. Semin Nucl Med. 2006;36:248-256. (Pubitemid 43817848)
10. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreatico-duodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg. 1995;221:721-723; discussion 731-733.
11. John T, Greig J, Carter D, et al. Carcinoma of the pancreas head and periampullary region. Ann Surg. 1995;221:156-164.
12. Conlon K, Dougherty E, Klimistra D, et al. The value of minimal access surgery in the staging of patients with potentially resectable peripancreatic malignancy. Ann Surg. 1996;223:134-140. (Pubitemid 26065205)
13. Fernandez del Castillo C, Rattner D, Warshaw A. Further experience with laparoscopy and peritoneal cytology in the staging of pancreatic cancer. Br J Surg. 1995;82:1127-1129.
14. American Cancer Society.Pancreatic cancer. Available at: www.cancer.org.
15. Hustinx R. PET imaging in assessing gastrointestinal tumors. Radiol Clin North Am. 2001;42:1123-1139.
16. Van Kouwen MC, Oyen WJ, Nagengast FM, et al. FDG-PET scanning in the diagnosis of gastrointestinal cancers. Scand J Gastroenterol Suppl. 2004;241: 85-92. (Pubitemid 40063536)
17. 18 F-fluorodeoxyglucose positron emission tomography for characterization and initial staging of pancreatic tumors. Gastroenterol Clin Biol. 2002;26:888-892. (Pubitemid 35334249)
18. Mansour JC, Schwartz L, Pandit-Taskar N, et al. The utility of F-18 fluoro-deoxyglucose whole body PET imaging for determining malignancy in cystic lesions of the pancreas. J Gastrointest Surg. 2006;10:1354-1360. (Pubitemid 44908996)
19. 18 F-fluorodeoxyglucose and 11C-acetate valuable in diagnosing indeterminate pancreatic masses? Scand J Surg. 2004;93:191-197. (Pubitemid 39482294)
20. Baiocchi GL, Portolani N, Bertagna F, et al. Possible additional value of 18FDG-PET in managing pancreas intraductal papillary mucinous neoplasm: preliminary results. J Exp Clin Cancer Res. 2008;27:10.
21. Sperti C, Pasquali C, Chierichetti F, et al. Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas. Ann Surg. 2001;234:675-680. (Pubitemid 33041771)
22. Lee TY, Kim MH, Park DH, et al. Utility of 18F-FDG PET/CT for differentiation of autoimmune pancreatitis with atypical pancreatic imaging flndings from pancreatica cancer. Am J Roentgenol. 2009;193:343-348.
23. Kwon S, Kim MH, Choi EK. The diagnostic criteria for autoimmune chronic pancreatitis: it is time to make a consensus. Pancreas. 2007;35:279-286. (Pubitemid 46588252)
24. Shimada K, Sakamoto Y, Sano T, et al. The role of paraaortic lymph node involvement on early recurrence and survival after macroscopic curative resection with extended lymphadenectomy for pancreatic carcinoma. J Am Coll Surg. 2006;203:345-352. (Pubitemid 44247756)
25. Nishiyama Y, Yamamoto Y, Yorke K, et al. Contribution of whole body FDG-PET to detection of distant metastasis in pancreatic cancer. Ann Nucl Med. 2005;19:491-497. (Pubitemid 41531270)
26. Kuwatani M, Kawakami H, Eto K, et al. Modalities for evaluating chemotherapeutic efflcacy and survival time in patients with advanced pancreatic cancer: comparison between FDG-PET, CT, and serum tumor markers. Intern Med. 2009;48:867-875.
27. Heinrich S, Schafer M, Weber A, et al. Neoadjuvant chemotherapy generates a signiflcant tumor response in resectable pancreatic cancer without increasing morbidity. Ann Surg. 2008;248:1014-1022.
28. Maemura K, Takao S, Shinchi H, et al. Role of positron emission tomography in decisions on treatment strategies for pancreatic cancer. J Hepatobiliary Pancreat Surg. 2006;13:435-441. (Pubitemid 44480247)
29. Sperti C, Pasquali C, Catalini S, et al. CA 19-9 as a prognostic index after resection for pancreatic cancer. J Surg Oncol. 1993;52:137-141. (Pubitemid 23078419)
30. Hosten N, Lemke AJ, Wiedenmann B, et al. Combined imaging techniques for pancreatic cancer. Lancet. 2000;356:909-910.
31. Beyer T, Towsend D, Brun T, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med. 2000;41:1369-1379. (Pubitemid 30643379)
32. 18 F-FDG PET/CT: !-stop-shop imaging for assessing the resectability of pancreatic cancer. J Nucl Med. 2008;49:1408-1413.
33. Herrmann K, Eckel F, Schmidt S, et al. In vivo characterization of proliferation for discriminating cancer from pancreatic pseudotumors. J Nucl Med. 2008;49:1437-1444.
34. Nagamachi S, Wakamatsu H, Kiyohara S, et al. Usefulness of a deepinspiration breath-hold 18F-FDG PET/CT technique in diagnosing liver, bile duct and pancreas tumors. Nucl Med Commun. 2009;30:326-332.